ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
September 24, 2020Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant... -
Higher dose of gefapixant hits endpoints in chronic cough trial
March 19, 2020MSD has revealed new topline efficacy results from two ongoing pivotal Phase III trials, evaluating gefapixant (MK-7264) in refractory or unexplained chronic cough. -
P2X3 agonist shows promise in relieving chronic cough
March 04, 2020A Phase IIb study by researchers at the University of Manchester, UK, has demonstrated that P2X3 agonist gefapixant relieves refractory or unexplained chronic cough.
Pharma Sources Insight January 2025
